Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Foot & Ankle
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.
Anesthesiology. 2025 01-Jun;():. 10.1097/aln.0000000000005460
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.
Anesthesiology. 2025 01-Jun;():. 10.1097/aln.0000000000005460
Foot & Ankle
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.
The New England journal of medicine. 2023 01-Aug;():. 10.1056/nejmoa2209870
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.
The New England journal of medicine. 2023 01-Aug;():. 10.1056/nejmoa2209870